Medical device maker Belluscura expects 20% tariff on products sold in US
(Reuters) – Medical device maker Belluscura on Wednesday said that its products sold in the United States could face levies of up to 20% and that the company was evaluating options to cut down on tariff and production costs in the long term. Belluscura, which focuses on developing portable oxygen technology and is headquartered in …
Medical device maker Belluscura expects 20% tariff on products sold in US Read More »






